Insights and views about cardiovascular safety of COX2 inhibitors
Wallentin, L.
Lakartidningen 102(9): 666; 668, 671
2005
ISSN/ISBN: 0023-7205 PMID: 15804041 Document Number: 588379
Document emailed within 1 workday
Related Documents
Green, L.J..; Yamauchi, P.S..; Kircik, L.H.. 2019: Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients with Psoriasis Journal of Drugs in Dermatology: Jdd 18(8): 776-788O'Brien, S.; McKeon, P. 1989: Monoamine oxidase inhibitors--new insights into old problems Irish Medical Journal 82(4): 146-147
Tiwaskar, M. 2019: INSIGHTS (INSITES) on DPP 4 Inhibitors (Gliptins) for Diabetes Management in India Journal of the Association of Physicians of India 67(10): 11-12
Grimes, D.A. 1992: The safety of oral contraceptives: epidemiologic insights from the first 30 years American Journal of Obstetrics and Gynecology 166(6 Part 2): 1950-1954
Guzon, O.J.; Dellsperger, K.C. 2006: Cardiovascular issues in dialysis patients: challenges and newer insights Advances in Peritoneal Dialysis. Conference on Peritoneal Dialysis 22: 111-115
McGrew, C.A. 1998: Insights into the AHA scientific statement concerning cardiovascular preparticipation screening of competitive athletes Medicine and Science in Sports and Exercise 30(10 Suppl): S351-S353
Lalude, O.O. 2013: Risk of cardiovascular events with hormonal contraception: insights from the Danish cohort study Current Cardiology Reports 15(7): 374
Zapolski, T.; Wysokiński, A. 2016: Current views on the interaction between the treatment of osteoporosis and cardiovascular diseases Wiadomosci Lekarskie 69(4): 665-674
Vesnina, Z.V.; Arsen'eva, I.A. 2012: Cardiorenal syndrome: currents views of relationships between renal and cardiovascular diseases Klinicheskaia Meditsina 90(7): 8-13
Wong, M.; Chowienczyk, P.; Kirkham, B. 2005: Cardiovascular issues of COX-2 inhibitors and NSAIDs Australian Family Physician 34(11): 945-948
Anita Petra Hardon 1992: The needs of women versus the interests of family planning personnel, policy-makers and researchers: Conflicting views on safety and acceptability of contraceptives Social Science and Medicine 35(6): 753-766
2016: NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac Prescrire International 25(167): 14-16
Jerie, P. 2005: VIOXX written off--and what next? COX-2 inhibitors and cardiovascular diseases Casopis Lekaru Ceskych 144(1): 4
Pellizzer, A.M.; Krum, H. 1996: ACE inhibitors in cardiovascular disease. which patient? which drug? which dose? Australian Family Physician 25(7): 1067-1069; 1072-3; 1076-1077
Doyle, J.C.; Mottram, D.R.; Stubbs, H. 1998: Prescribing of ACE inhibitors for cardiovascular disorders in general practice Journal of Clinical Pharmacy and Therapeutics 23(2): 133-136
Richard, E.; van Gool, W.A. 2006: Cholinesterase inhibitors in dementia: the precarious balance between efficacy and safety Nederlands Tijdschrift Voor Geneeskunde 150(10): 530-532
Lebwohl, M.; Gower, T. 2006: A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis Medgenmed: Medscape General Medicine 8(4): 8
Goldman, L.S.; Alexander, R.C.; Luchins, D.J. 1986: Monoamine oxidase inhibitors and tricyclic antidepressants: comparison of their cardiovascular effects Journal of Clinical Psychiatry 47(5): 225-229
Edgren, R.A. 1981: On oral contraceptive safety: cardiovascular problems International Journal of Fertility 26(4): 241-244
Langer, A. 1998: Safety of calcium channel blockers in cardiovascular disease Circulation 98(25): 2933